Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The co… Read more
Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.103x
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has a cash flow conversion efficiency ratio of 0.103x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥670.83 Million) by net assets (CN¥6.50 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Allist Pharmaceuticals Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TUI AG
PINK:TUIFF
|
-2.866x |
|
Focuslight Technologies Inc. A
SHG:688167
|
N/A |
|
Sumitomo Heavy Industries Ltd
F:SSM1
|
0.025x |
|
Kinsus Interconnect Technology Corp
TW:3189
|
0.088x |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
-0.115x |
|
Indivior PLC Ordinary Shares
NASDAQ:INDV
|
0.198x |
|
Hannover Re
PINK:HVRRY
|
0.132x |
|
Red Rock Resorts Inc
NASDAQ:RRR
|
0.509x |
Annual Cash Flow Conversion Efficiency for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.28 Billion | CN¥1.57 Billion | 0.296x | +74.98% |
| 2023-12-31 | CN¥3.98 Billion | CN¥674.65 Million | 0.169x | +489.25% |
| 2022-12-31 | CN¥3.19 Billion | CN¥91.63 Million | 0.029x | +191.84% |
| 2021-12-31 | CN¥2.97 Billion | CN¥29.29 Million | 0.010x | +114.41% |
| 2020-12-31 | CN¥2.88 Billion | CN¥-196.75 Million | -0.068x | +68.78% |
| 2019-12-31 | CN¥1.18 Billion | CN¥-259.37 Million | -0.219x | +84.00% |
| 2018-12-31 | CN¥71.04 Million | CN¥-97.25 Million | -1.369x | -5261.91% |
| 2017-12-31 | CN¥381.26 Million | CN¥10.11 Million | 0.027x | -- |